Migraines are a debilitating neurological condition that produces moderate to intense headaches that last for hours or even days. Patients who suffer from migraines often search desperately for treatment options in order to reduce their symptoms.
But if we consider that regular treatment plans based on NSAIDs or opioid pain drugs can vary in their outcomes and possible side effects, the need to find another therapeutic option to solve this symptomatology becomes mandatory.
Fortunately, a new type of medication known as CGRP (calcitonin gene-related peptide) inhibitors or monoclonal antibodies has been used for preventing acute and chronic migraine symptoms, being capable of reducing the headache episodes per month in these patients.
CGRP is a protein that can be found in the physiology of the trigeminal nerve, the cranial nerve that provides almost every sensation to the head. This nerve plays an important role in the origin of migraines due to its capacity of dilating cranial blood vessels and promoting neurogenic inflammation.
This is where CGRP monoclonal antibodies come into play, working pharmacologically by blocking the CGRP receptors or the protein itself. This way, the functions stated above do not activate, preventing the migraine from happening in the first place.
For now, the FDA has approved four CGRP inhibitors: Aimovig, Ajovy, Vyepti, and Emgality, who share similarities in regards to their effectiveness in preventing acute and chronic migraines. In fact, studies have established the important role that CGRP inhibitors have belonging to the therapeutic options for migraine control.
Additionally, a scientific publication showed the combination of CGRP monoclonal antibodies and onabotulinumtoxinA is more effective than either therapy alone for migraine prevention.
OnabotulinumtoxinA was already used alone for the treatment of migraine symptoms because of its ability to inhibit the activation of the sensory reach of the trigeminal and facial nerves, thereby dimming the painful signal that promoted migraine. In addition, this toxin attenuates the release of neuropeptides and neurotransmitters in the synaptic space, modulating such activity.
Combining these two pharmacological elements was associated with clinically significate benefits and good tolerance from the patients in the study.
By scheduling an appointment with experts like Dr. Edward A. Nash over at Progressive Pain & Rehabilitation, we can make you return to your daily activities in the shortest possible time through the application of preventative and regenerative care techniques that will give you the boost your body needs to heal itself and be capable of face everything in its way.
For more information about this topic and so much more, contact us at 346-220-8063. Our team of experts based in the luxuriously planned community of The Woodlands, TX, will be available during working hours to answer all your inquiries and support you in your path to wellness.
Or, if you prefer, schedule your appointment at https://drnashcares.com/appointment/ and you will receive the proper attention your case requires.